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BACKGROUND: L i t t l ei sk n o w na b o u tp h y s i c i a n s ’
screening patterns for liver cancer despite its rising
incidence.
OBJECTIVE: Describe physician factors associated
with liver cancer screening.
DESIGN: Mailed survey.
PARTICIPANTS: Physicians practicing in family prac-
tice, internal medicine, gastroenterology, or nephrology
in 3 northern California counties in 2004.
MEASUREMENTS: Sociodemographic and practice
measures, liver cancer knowledge, attitudes, and self-
reported screening behaviors.
RESULTS: The response rate was 61.8% (N=459).
Gastroenterologists (100%) were more likely than Inter-
nists (88.4%), family practitioners (84.2%), or nephrol-
ogists (75.0%) to screen for liver cancer in high-risk
patients (p=0.016). In multivariate analysis, screeners
were more likely than nonscreeners to think that
screening for liver cancer reduced mortality (odds ratio
[OR] 1.60, CI 1.09–2.34) and that not screening was a
malpractice risk (OR 1.88, CI 1.29–2.75). Screeners
were more likely than nonscreeners to order any
screening test if it was a quality of care measure (OR
4.39, CI 1.79–10.81).
CONCLUSIONS: Despite debate about screening effica-
cy, many physicians screen for liver cancer. Their
screening behavior is influenced by malpractice and
quality control concerns. More research is needed to
develop better screening tests for liver cancer, to
evaluate their effectiveness, and to understand how
physicians behave when there is insufficient evidence.
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BACKGROUND
Liver cancer is the fourth most common cancer worldwide, and
its incidence is rising in the United States.
1,2 Approximately
2 million Americans are at risk, particularly those with
hepatitis C cirrhosis or chronic hepatitis B.
3,4 Ethnic
minorities, particularly Asian-Americans, have high rates of
viral hepatitis and liver cancer.
5
Current screening tests include serum alpha-fetoprotein
(AFP) and radiologic imaging. Screening detects smaller
tumors at diagnosis and may prolong survival, but lead-time
bias is a problem.
6 Positive predictive values range from 46% to
58% for AFP, 69% to 73% for ultrasound, and 67% for
computed tomography (CT) in cirrhotic patients but are lower
in those without cirrhosis.
7 The National Cancer Institute (NCI)
concluded that there is no evidence for a mortality reduction
when screening high-risk patients.
8 However, some guidelines
recommend screening of high-risk patients, and most hepatol-
ogists screen.
9,10 Because of the conflicting evidence and
recommendations, this study aimed to describe liver cancer
screening practices among primary care physicians (PCPs) and
gastroenterologists, who provide care to most high-risk
patients, and nephrologists, as hemodialysis patients also
have a high prevalence of viral hepatitis.
METHODS
The study sample was drawn from the 2003 American Medical
Association (AMA) Masterfile. Eligible physicians were board
certified in family practice, internal medicine, gastroenterology,
or nephrology and had office-based practices in 3 northern
California counties with high proportions of ethnic minorities.
The sample included all gastroenterologists, nephrologists,
Asian-American PCPs, and 50% of randomly selected non-
Asian PCPs. We oversampled Asian-American physicians
because they may have heightened awareness of liver cancer
and different screening behaviors.
11,12 Excluding those whose
address did not match telephone directories and medical
center listings, the sample consisted of 743 physicians.
The survey instrument was developed, pilot-tested with 20
physicians, and revised. In 2004, the survey was mailed,
followed by a second mailing in 4 weeks and a reminder card
6 weeks later. Respondents chose $10 or a chance for $100 in
gift cards as incentives. The Institutional Review Board of the
University of California, San Francisco approved the protocol.
Measures
Physician sociodemographic measures were age, gender, race,
languages spoken, and country of birth. Practice measures
included country of medical training, specialty, years in
practice, type of practice, number of patients seen daily, and
proportions of patients with public health insurance or who
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523were non-English speakers. Using a 5-point Likert scale from 1
(strongly disagree) to 5 (strongly agree), the survey included 7
items to assess attitude toward and knowledge about liver
cancer, its risks, and its screening. There were also 5 questions
on what influenced the respondent to order any screening test.
The dependent variable was screening for liver cancer in high-
risk patients, defined as responding “yes” to the question “Do
you screen for liver cancer in high-risk patients?” Respondents
Table 1. Physician Characteristics, Knowledge, Attitudes, and Intention Regarding Screening for Liver Cancer Compared to Screening
Practice
Screeners
(n=406)
Nonscreeners
(n=53)
Total
(n=459)
p value
Percentage or mean (standard deviation)
Physician sociodemographics
Sex, male 60.1 62.3 60.3 0.88
Age, in years 45.2 (11.3) 44.6 (9.7) 45.1(11.1) 0.69
Race
White 41.9 52.8 43.1 0.35
Asian 53.7 45.3 52.7
Other 4.4 1.9 4.1
Birthplace in the United States 54.9 67.9 56.4 0.08
Speaks language other than English
None 31.5 34.0 31.8 0.28
Asian 44.3 34.0 43.1
Other 24.1 32.1 25.0
Trained in U.S. medical school 79.4 81.1 79.6 0.86
Primary medical specialty
General internal medicine 64.2 64.1 64.2 0.003
Family practice 21.1 30.2 22.2
Gastroenterology 12.4 0.0 11.0
Nephrology 2.2 5.7 2.6
Years in specialty 13.6 (10.9) 14.6 (10.7) 13.8 (10.8) 0.56
Practice characteristics
Primary medical practice
Private 53.0 62.3 54.0 0.19
University 17.5 20.7 17.9
Health maintenance organization (HMO) 21.4 9.4 20.0
Other 8.1 7.5 8.1
Average number of patients seen each day 19.6 (10.9) 17.5 (8.9) 19.3 (7.5) 0.06
Proportion of patients who are...
Asian 30.7 (27.0) 24.9 (22.0) 30.0(26.5) 0.13
Non-English speaking 20.8 (23.7) 16.5 (22.9) 20.3 (23.6) 0.23
Aged 18–39 years 23.2 (13.9) 22.1 (17.8) 23.0 (14.4) 0.61
Aged 40–64 years 37.8 (14.9) 30.1 (16.0) 36.9 (15.2) <0.001
Aged 65+ years 35.2 (20.0) 39.0 (27.2) 35.6 (21.0) 0.21
Proportion of patients with...
Public health insurance 29.0 (24.6) 33.7 (29.9) 29.6 (25.2) 0.20
Private managed care health insurance 37.0 (32.5) 34.7 (31.9) 36.8 (32.4) 0.63
Private non-managed care health insurance 21.0 (23.0) 17.3 (21.7) 20.3 (22.8) 0.28
No health insurance 7.6 (15.8) 9.7 (19.7) 7.8 (16.3) 0.36
Physician knowledge (scale 1–5
†)
Asian-Americans have a high incidence of liver cancer compared to Whites 4.6 (0.7) 4.4 (0.9) 4.5 (0.7) 0.18
Patients with chronic hepatitis B have a higher risk of liver cancer
than patients with chronic hepatitis C
3.4 (1.2) 3.2 (1.2) 3.4 (1.2) 0.21
Asian-Americans have a lower prevalence of chronic hepatitis B
compared to Whites
††
1.5 (0.9) 1.9 (1.2) 1.5 (1.0) 0.008
Screening for colon cancer reduces colon cancer mortality 4.7 (0.6) 4.6 (0.7) 4.7 (0.6) 0.17
Physician attitudes (scale 1–5
†)
Screening for liver cancer among high-risk patients reduces liver cancer mortality 3.8 (0.9) 3.3 (1.0) 3.8 (0.9) <0.001
Screening for liver cancer among high-risk patients is cost-effective 3.5 (0.9) 3.0 (0.9) 3.4 (1.0) <0.001
Not screening for liver cancer among high-risk patients is a malpractice risk 3.5 (1.0) 2.8 (0.9) 3.4 (1.0) <0.001
Physician intention regarding cancer screening
†††
Would order a screening test if...
there is evidence that it decreases mortality 94.3 88.7 93.7 0.11
recommended by a national organization 72.7 73.6 72.8 0.89
see more of the cancer in practice 25.4 15.1 24.2 0.10
a patient asks for it 49.5 43.4 48.8 0.40
used as a quality-of-care measure 35.5 15.1 33.1 0.003
covered by health insurance 27.1 20.7 26.4 0.33
†Likert scale from 1=strongly disagree to 5=strongly agree
††Incorrect answer
†††Percentage responding “yes”
524 Nguyen et al.: Liver Cancer Screening JGIMwere subsequently asked which patients they considered
“high-risk” and to describe the tests and intervals employed.
Analysis
The hypothesis was that gastroenterologists were more likely
to screen for liver cancer than PCPs. Descriptive statistics were
computed for screeners and non-screeners. To examine the
association of each variable with screening behavior, Fisher’s
exact test or chi-square test for categorical measures and
Student’s t test for continuous measures were used in
bivariate analyses. A multivariate model was developed initial-
ly including all variables with a bivariate p<0.20 for the
association with screening behavior. This was followed by a
backward elimination procedure. Physician age, gender, and
race were forced into the final model. Gastroenterologists were
excluded because their screening rate was 100%. All analyses
utilized SAS version 9.1 (SAS Institute, 1999).
RESULTS
The overall response rate was 61.8%, with 71.4% of gastro-
enterologists, 65.0% of family practitioners, 60.3% of general
internists, and 48.0% of nephrologists responding. Compared
to responders (N=459), nonresponders (N=284) were older
(mean 50.5 vs 45.1 years) and had lower proportions of women
(30.9% vs 39.7%) and Asians (34.4% vs 52.7%). Most respond-
ers (88.5%) reported screening for liver cancer in high-risk
patients.
Physicians identified as high-risk conditions chronic hepa-
titis B with cirrhosis (86.1% of physicians), hepatitis C with
cirrhosis (83.0%), chronic hepatitis B without cirrhosis
(72.3%), and non-B non-C cirrhosis (57.9%). More than half
(56.6%) used 2 tests to screen, with 52.3% using both AFP and
ultrasound (32.9% using both at intervals of ≤12 months) and
1.7% using both AFP and CT. Only 4.1% used 1 test to screen
(3.2% AFP and 0.9% ultrasound), whereas 26.5% used all 3
tests to screen.
Physician specialty was significantly associated with screen-
ing with 100% of gastroenterologists, 88.4% of General Inter-
nists, 84.2% of family practitioners, and 75.0% of nephrologists
reporting screening (p=0.016; Table 1). Screeners were more
likely than nonscreeners to know that the prevalence of chronic
hepatitis B was higher among Asian Americans than Whites (p=
0.008). Screeners were more likely to think that screening
reducedmortalityandwascost-effective,andthatnotscreening
was a malpractice risk (all p<0.001). Screeners were more likely
than nonscreeners to report they were influenced by quality of
care considerations when ordering any screening test (p=
0.003).
Compared to general internists, gastroenterologists were
more likely to know that the risk for liver cancer was higher
among patients with hepatitis B than C (p=0.01) and to believe
that not screening was a malpractice risk (p=0.05) but less
likely to use a screening test that was a quality measure (p=
0.03). Family practitioners were more likely than general
internists to believe that not screening was a malpractice risk
(p=0.05).
In multivariate analysis (Table 2), physicians were more
likely to screen for liver cancer if they thought that screening
reduced liver cancer mortality (OR 1.60, CI 1.09–2.34) and
that not screening was a malpractice risk (OR 1.88, CI 1.29–
2.75). Screeners were more likely than nonscreeners to order a
test if its use was a quality of care measure (OR 4.39, CI 1.79–
10.81).
DISCUSSION
This study found that many physicians responding to this
survey in northern California reported screening for liver
cancer in high-risk patients. The proportion who reported
screening was similar to those reporting screening for prostate
cancer, another controversial test.
13,14 Our finding that gas-
troenterologists were more likely to screen for liver cancer than
PCPs and nephrologists confirmed our hypothesis that specia-
lists were more likely to screen for cancer in their specialty.
However, the rate of screening was surprisingly high, with
100% of gastroenterologists reporting screening, whereas the
proportion of PCPs who screened was similar to that reported
by hepatologists in an earlier study.
10 These findings indicate
that despite the lack of clear evidence of effectiveness, many
physicians screen for liver cancer in high-risk patients.
Early prospective studies of liver cancer screening did not
have control groups, found that the tests had poor character-
istics, or did not show an effect on tumor size or mortality.
15–17
Two recent randomized controlled trials from China reported
conflicting results. One showed that screening among 18,816
hepatitis B-infected participants reduced mortality by 37%.
18
Table 2. Multivariate Logistic Model Identifying Physician Factors
Associated with Screening for Liver Cancer (n=348)*
Screen for liver cancer
odds ratio (95%
confidence interval)
Age, 5-year increments 1.00 (0.97, 1.04)
Male sex (female=reference category
[ref.])
0.73 (0.34, 1.58)
Asian race (non-Asian=ref.) 1.08 (0.48, 2.42)
Birthplace in U.S. 0.56 (0.25, 1.26)
Medical specialty (general internal
medicine=ref.)
Family practice 0.99 (0.44, 2.21)
Nephrology 0.39 (0.07, 2.13)
Primary medical practice (private=
ref.)
University 1.48 (0.58, 3.76)
Health Maintenance Organization (HMO) 3.18 (0.96, 10.57)
Other 0.99 (0.24, 4.05)
Asian Americans have a lower
prevalence of chronic hepatitis B
compared to Whites
†
0.74 (0.54, 1.01)
Screening for liver cancer among
high-risk patients reduces liver
cancer mortality
1.60 (1.09, 2.34)
Not screening for liver cancer among
high-risk patients is a malpractice
risk
1.88 (1.29, 2.75)
Would order a cancer screening test
if it is a quality of care measure
4.39 (1.79, 10.81)
Model characteristics: R-square=0.271; Hosmer–Lemeshow goodness-
of-fit p value=0.546
*Excludes gastroenterologists since 100% screened for liver cancer
†Incorrect answer
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19 The NCI interpreted
these data as showing no mortality benefit, but in our survey,
screeners thought that liver cancer screening reduced mortal-
ity. This may reflect lack of knowledge of the evidence,
disagreement about its interpretation, or selective use of the
evidence to support their behavior.
Perhaps owing to the conflicting evidence and recommenda-
tions, screeners were susceptible to factors such as fear of
malpractice and quality control. Fear of malpractice has been
associated with screening behaviors in other studies.
10,20
Because liver cancer has a high case fatality rate, can occur
among young adults with hepatitis B, and some guidelines do
recommend screening, physicians may perceive a high risk of
being sued for failure to screen. Whereas liver cancer screening
is not usually a quality of care measure, quality control
concerns in general affected screeners more than nonscre-
eners, although the effect varied by specialty.
The high rate of screening found in this sample may be
caused by several biases. First, the response rate of 61.8% was
low, although not unusually so for published surveys on
screening behaviors among community-based physicians.
The only published survey on liver cancer screening had a
response rate of 54%.
10 Second, respondents may have been
more interested in screening and screened more than non-
respondents, especially because response rates were highest
among gastroenterologists and Asian-American physicians.
Nonetheless, even if no one screened among nonresponders,
the reported screening rate in this sample would be 54.6%.
Third, self-reports overestimate actual behaviors, and respon-
ders, knowing the survey’s purpose, may have overstated their
screening behaviors. However, this bias, if true, indicates that
responders perceive screening as the socially desirable out-
come. Finally, the survey area had a high proportion of high-
risk patients, and the results may not be generalizable to areas
with low prevalence of high-risk patients.
Despite debate regarding effectiveness, many physicians
screen for liver cancer in high-risk patients. When the evidence
is unclear and the stakes are high, these physicians are
influenced by concerns about malpractice and quality control.
Along with the need to improve screening tests and evaluate
their effectiveness, research is also needed to understand and
influence how physicians behave when facing inconsistencies
in the scientific literature.
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